大脑状态转移生成对抗网络用于解码阿尔茨海默氏症疾病中的个体化缩
IEEE journal of biomedical and health informatics
|August 22, 2023
概括
这项研究引入了一种新的深度学习模型,BrainStatTrans-GAN,用于从患者扫描中生成健康的大脑图像. 这使得可以检测到个性化的脑缩,从而改善阿尔茨海默病的诊断和精准医学.
科学领域:
- 神经成像是一种神经成像.
- 计算神经科学是一种神经科学.
- 人工智能在医学中的应用
背景情况:
- 深度学习对于使用脑图像的计算分析来诊断大脑疾病至关重要.
- 目前的群体分析方法缺乏检测个体病理变化的能力,阻碍了个性化医疗.
- 对疾病变异的个性化解释对于精准医学和有效的治疗策略至关重要.
研究的目的:
- 提出一种新的生成对抗网络 (BrainStatTrans-GAN) 来从患病的人中生成健康的大脑图像.
- 为了实现个性化大脑缩的解码,以加强疾病诊断和解释.
- 开发一个基于残留的多层融合网络 (RMFN) 以更准确的疾病诊断.
主要方法:
- 开发了一个BrainStatTrans-GAN,包括生成器,区分器和状态区分器,用于生成患者大脑图像的健康对应物.
- 实施了具有地位歧视者的对抗性学习,以克服对健康和患病的大脑图像数据的缺乏.
- 通过计算生成的健康图像和原始患者图像之间的残余量来量化病态的大脑变化.
- 使用基于残留的多层融合网络 (RMFN) 进行最终的疾病诊断.
主要成果:
- 拟议的BrainStatTrans-GAN成功地从患者扫描中生成健康的大脑图像,从而能够量化个性化大脑缩.
- 基于残留的方法有效地模拟了个体主体层面的病理变化.
- 在3个数据集中的1,739名受试者的T1加权MRI数据上的实验结果证明了该方法的有效性.
- 与现有的小组智能方法相比,这种方法促进了更准确的疾病诊断和解释.
结论:
- 该BrainStatTrans-GAN方法使个性化大脑缩模型成为可能,这对于神经系统疾病的精准医学至关重要.
- 这种方法提高了像阿尔茨海默氏症这样的大脑疾病的诊断准确性和解释性.
- 这项研究强调了生成对抗网络的潜力,用于个性化计算神经成像分析.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.3K
相关概念视频
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
